AR004512A1 - Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivados - Google Patents
Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivadosInfo
- Publication number
- AR004512A1 AR004512A1 ARP960104355A AR10435596A AR004512A1 AR 004512 A1 AR004512 A1 AR 004512A1 AR P960104355 A ARP960104355 A AR P960104355A AR 10435596 A AR10435596 A AR 10435596A AR 004512 A1 AR004512 A1 AR 004512A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- procedure
- preparation
- carry out
- benzotiazolone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/24—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Derivados de benzotiazolona de la fórmula I, que incluye los isómeros ópticos del mismo en el cual X representa-SO2NH- o -NHSO2-,p, q, y, rindependientemente representan 2 ó 3 , Y representa tienilo optativamente sustituido por alquilo oh alógeno, o feniltio-o fenilo optativamente sustituídopor alquilo o halógeno, y cada R presenta, independientemente, H o alquilo, y sales, ésteres y amidas farmacéuticamente aceptables del mismo. Se describeademás un procedimiento para supreparació n, un compuesto intermediario útil para llevar a cabo dicho procedimiento y una composición farmacéutica quecomprende dichos derivados. Los compuestos son agonistas del receptor de la dopamina DA2 y agonistas del adrenorreceptor B2y están ind icados paraenfermedades obstructivas de las vías aéreas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9518952.8A GB9518952D0 (en) | 1995-09-15 | 1995-09-15 | Compounds |
| GBGB9614346.6A GB9614346D0 (en) | 1996-07-10 | 1996-07-10 | Benzothiazolone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR004512A1 true AR004512A1 (es) | 1998-12-16 |
Family
ID=26307771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960104355A AR004512A1 (es) | 1995-09-15 | 1996-09-13 | Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivados |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US5846989A (es) |
| EP (1) | EP0850232B1 (es) |
| JP (1) | JP3213327B2 (es) |
| KR (1) | KR19990044674A (es) |
| CN (2) | CN1073098C (es) |
| AR (1) | AR004512A1 (es) |
| AT (1) | ATE190610T1 (es) |
| AU (1) | AU706094B2 (es) |
| BR (1) | BR9610316A (es) |
| CA (1) | CA2231003A1 (es) |
| CY (1) | CY2227B1 (es) |
| CZ (1) | CZ74098A3 (es) |
| DE (1) | DE69607183T2 (es) |
| EE (1) | EE03395B1 (es) |
| ES (1) | ES2146901T3 (es) |
| GR (1) | GR3033681T3 (es) |
| HK (1) | HK1008781A1 (es) |
| HU (1) | HUP9802393A3 (es) |
| IL (4) | IL141956A0 (es) |
| IS (1) | IS4679A (es) |
| MY (1) | MY113518A (es) |
| NO (1) | NO310721B1 (es) |
| NZ (4) | NZ318007A (es) |
| PL (1) | PL325517A1 (es) |
| PT (1) | PT850232E (es) |
| SK (1) | SK282394B6 (es) |
| TR (1) | TR199800457T2 (es) |
| TW (1) | TW356468B (es) |
| WO (1) | WO1997010227A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5187991B2 (ja) * | 1997-10-17 | 2013-04-24 | アーク・セラピューティックス・リミテッド | レニン−アンジオテンシン系の阻害剤の使用 |
| SE0004750D0 (sv) * | 2000-12-19 | 2000-12-19 | Astrazeneca Ab | Novel formulation |
| GB0218629D0 (en) * | 2002-08-09 | 2002-09-18 | Novartis Ag | Organic compounds |
| AR040962A1 (es) * | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| CA2543858C (en) * | 2003-11-21 | 2014-04-15 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| CN101282950B (zh) * | 2005-08-09 | 2012-09-12 | 阿斯利康(瑞典)有限公司 | 新颖的苯并噻唑酮衍生物 |
| TW200740781A (en) * | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2008075025A1 (en) * | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| JP2011524896A (ja) | 2008-06-18 | 2011-09-08 | アストラゼネカ・アクチエボラーグ | 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体 |
| JP2011524897A (ja) * | 2008-06-20 | 2011-09-08 | アストラゼネカ・アクチエボラーグ | β２−アドレナリン受容体活性の調節のための、４−ヒドロキシ−２−オキソ−２，３−ジヒドロ−１，３−ベンゾチアゾール−７−イル化合物を含む医薬組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314944A (en) * | 1980-08-22 | 1982-02-09 | Smithkline Corporation | 4-Aminoalkyl-7-hydroxy-2(3H)-indolones |
| US4452808A (en) * | 1982-12-07 | 1984-06-05 | Smithkline Beckman Corporation | 4-Aminoalkyl-2(3H)-indolones |
| GB8426200D0 (en) * | 1984-10-17 | 1984-11-21 | Glaxo Holdings Ltd | Chemical compounds |
| US4554284A (en) * | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones |
| US4554287A (en) * | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones |
| AU4945185A (en) * | 1984-11-08 | 1986-05-15 | Syntex (U.S.A.) Inc. | Dialkyl aminoethylaniline derivatives |
| DE3728695A1 (de) * | 1987-08-25 | 1989-03-09 | Schering Ag | Neue benzimidazol-derivate |
| GB9024208D0 (en) * | 1990-11-07 | 1990-12-19 | Salutar Inc | Compounds |
| IE914003A1 (en) * | 1990-11-20 | 1992-05-20 | Astra Pharma Prod | Biologically Active Amines |
| GB9210632D0 (en) * | 1992-05-19 | 1992-07-01 | Fisons Plc | Compounds |
| GB9211172D0 (en) * | 1992-05-27 | 1992-07-08 | Fisons Plc | Compounds |
-
1996
- 1996-09-11 TW TW085111075A patent/TW356468B/zh active
- 1996-09-12 AU AU69371/96A patent/AU706094B2/en not_active Ceased
- 1996-09-12 ES ES96930256T patent/ES2146901T3/es not_active Expired - Lifetime
- 1996-09-12 CZ CZ98740A patent/CZ74098A3/cs unknown
- 1996-09-12 CN CN96198311A patent/CN1073098C/zh not_active Expired - Fee Related
- 1996-09-12 WO PCT/GB1996/002247 patent/WO1997010227A1/en not_active Application Discontinuation
- 1996-09-12 BR BR9610316A patent/BR9610316A/pt not_active Application Discontinuation
- 1996-09-12 IL IL14195696A patent/IL141956A0/xx unknown
- 1996-09-12 IL IL12363996A patent/IL123639A/en not_active IP Right Cessation
- 1996-09-12 JP JP51175297A patent/JP3213327B2/ja not_active Expired - Fee Related
- 1996-09-12 NZ NZ318007A patent/NZ318007A/xx unknown
- 1996-09-12 SK SK295-98A patent/SK282394B6/sk unknown
- 1996-09-12 IL IL141954??A patent/IL141954A0/xx unknown
- 1996-09-12 CA CA002231003A patent/CA2231003A1/en not_active Abandoned
- 1996-09-12 US US08/776,770 patent/US5846989A/en not_active Expired - Lifetime
- 1996-09-12 PL PL96325517A patent/PL325517A1/xx unknown
- 1996-09-12 KR KR1019980701929A patent/KR19990044674A/ko not_active Application Discontinuation
- 1996-09-12 AT AT96930256T patent/ATE190610T1/de not_active IP Right Cessation
- 1996-09-12 DE DE69607183T patent/DE69607183T2/de not_active Expired - Fee Related
- 1996-09-12 HU HU9802393A patent/HUP9802393A3/hu unknown
- 1996-09-12 EP EP96930256A patent/EP0850232B1/en not_active Expired - Lifetime
- 1996-09-12 PT PT96930256T patent/PT850232E/pt unknown
- 1996-09-12 EE EE9800069A patent/EE03395B1/xx not_active IP Right Cessation
- 1996-09-12 TR TR1998/00457T patent/TR199800457T2/xx unknown
- 1996-09-12 IL IL14195596A patent/IL141955A0/xx unknown
- 1996-09-13 MY MYPI96003788A patent/MY113518A/en unknown
- 1996-09-13 AR ARP960104355A patent/AR004512A1/es not_active Application Discontinuation
-
1998
- 1998-03-04 IS IS4679A patent/IS4679A/is unknown
- 1998-03-12 NO NO19981104A patent/NO310721B1/no unknown
- 1998-07-29 HK HK98109506A patent/HK1008781A1/xx not_active IP Right Cessation
- 1998-09-02 US US09/146,047 patent/US6008365A/en not_active Expired - Lifetime
- 1998-09-02 US US09/146,046 patent/US5977384A/en not_active Expired - Lifetime
- 1998-09-02 US US09/146,048 patent/US6080869A/en not_active Expired - Lifetime
- 1998-09-02 US US09/145,281 patent/US5973167A/en not_active Expired - Lifetime
- 1998-10-19 NZ NZ332397A patent/NZ332397A/xx unknown
- 1998-10-19 NZ NZ332396A patent/NZ332396A/xx unknown
- 1998-10-19 NZ NZ332395A patent/NZ332395A/xx unknown
-
2000
- 2000-06-14 GR GR20000401368T patent/GR3033681T3/el not_active IP Right Cessation
- 2000-12-30 CN CN00137051A patent/CN1356323A/zh active Pending
-
2001
- 2001-07-20 CY CY0100016A patent/CY2227B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR004512A1 (es) | Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivados | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| ECSP024399A (es) | Derivados de benzotiazol | |
| ECSP014097A (es) | Derivados de tiofeno utiles como agentes anticancerosos | |
| ECSP034744A (es) | Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos | |
| AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
| PA8491501A1 (es) | Acidos oxamicos y derivados como ligandos de receptores tiroideos | |
| HN2003000215A (es) | Nuevos derivados de glicocido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos. | |
| UY28339A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| CR7743A (es) | Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf) | |
| GT199800180A (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos. | |
| ES2081187T3 (es) | Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| PA8452001A1 (es) | Derivados de macrolidos c-4" sustituidos | |
| UY28101A1 (es) | Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer | |
| UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| AR014747A1 (es) | Derivados de piperidina, un procedimiento para prepararlos, el empleo de los mismos para preparar un medicamento, una composicion farmaceutica que loscontiene y un procedimiento para obtener esta composicion farmaceutica | |
| UY29823A1 (es) | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones | |
| MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| MX9304524A (es) | Nuevos derivados de indol y composiciones que los contienen. | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| BR0311642A (pt) | Formulação de divalproex de sódio de liberação aumentada | |
| PE20021016A1 (es) | Conjugados de pregabalina-lactosa | |
| AR048716A1 (es) | Derivados de acido pentenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas | |
| ES2156616T3 (es) | (r)-5-bromo-n-(1-etil-4-metilhexahidro-1h-1,4-diazepan-6-il)-2-metoxi-6-metilamino-3-piridincarboxamida, procedimiento para su produccion y composicion medicinal que la contiene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |